CN116171153B - 用于调节剪接的组合物 - Google Patents
用于调节剪接的组合物Info
- Publication number
- CN116171153B CN116171153B CN202180062419.8A CN202180062419A CN116171153B CN 116171153 B CN116171153 B CN 116171153B CN 202180062419 A CN202180062419 A CN 202180062419A CN 116171153 B CN116171153 B CN 116171153B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- methyl
- fluoro
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061742P | 2020-08-05 | 2020-08-05 | |
| US63/061,742 | 2020-08-05 | ||
| PCT/US2021/044528 WO2022031838A1 (en) | 2020-08-05 | 2021-08-04 | Compositions for modulating splicing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116171153A CN116171153A (zh) | 2023-05-26 |
| CN116171153B true CN116171153B (zh) | 2025-11-21 |
Family
ID=80117649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180062419.8A Active CN116171153B (zh) | 2020-08-05 | 2021-08-04 | 用于调节剪接的组合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230331718A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192454B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7895554B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116171153B (cg-RX-API-DMAC7.html) |
| AR (1) | AR123150A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320763A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188104A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300352B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001558A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202216697A (cg-RX-API-DMAC7.html) |
| UY (1) | UY39368A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022031838A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) * | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| GB202106871D0 (en) * | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114007613A (zh) * | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2579949T3 (es) | 2010-02-05 | 2016-08-17 | Heptares Therapeutics Limited | Derivados de 1,2,4-triazin-4-amina |
| MX2020001425A (es) * | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| JP2021521200A (ja) * | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| WO2020163248A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| EP3920918A4 (en) | 2019-02-05 | 2022-11-16 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| WO2022031998A2 (en) * | 2020-08-05 | 2022-02-10 | Skyhawk Therapeutics, Inc. | Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing |
-
2021
- 2021-08-04 CA CA3188104A patent/CA3188104A1/en active Pending
- 2021-08-04 MX MX2023001558A patent/MX2023001558A/es unknown
- 2021-08-04 UY UY0001039368A patent/UY39368A/es not_active Application Discontinuation
- 2021-08-04 CN CN202180062419.8A patent/CN116171153B/zh active Active
- 2021-08-04 WO PCT/US2021/044528 patent/WO2022031838A1/en not_active Ceased
- 2021-08-04 AU AU2021320763A patent/AU2021320763A1/en active Pending
- 2021-08-04 EP EP21852740.6A patent/EP4192454B1/en active Active
- 2021-08-04 TW TW110128712A patent/TW202216697A/zh unknown
- 2021-08-04 KR KR1020237007640A patent/KR20230048106A/ko active Pending
- 2021-08-04 IL IL300352A patent/IL300352B1/en unknown
- 2021-08-04 AR ARP210102177A patent/AR123150A1/es unknown
- 2021-08-04 JP JP2023508065A patent/JP7895554B2/ja active Active
-
2023
- 2023-01-31 US US18/162,085 patent/US20230331718A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114007613A (zh) * | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230331718A1 (en) | 2023-10-19 |
| MX2023001558A (es) | 2023-04-26 |
| CN116171153A (zh) | 2023-05-26 |
| EP4192454B1 (en) | 2026-04-22 |
| UY39368A (es) | 2022-01-31 |
| AR123150A1 (es) | 2022-11-02 |
| WO2022031838A1 (en) | 2022-02-10 |
| EP4192454A1 (en) | 2023-06-14 |
| IL300352B1 (en) | 2026-06-01 |
| KR20230048106A (ko) | 2023-04-10 |
| CA3188104A1 (en) | 2022-02-10 |
| TW202216697A (zh) | 2022-05-01 |
| AU2021320763A1 (en) | 2023-03-30 |
| JP7895554B2 (ja) | 2026-07-28 |
| EP4192454C0 (en) | 2026-04-22 |
| IL300352A (en) | 2023-04-01 |
| JP2023538524A (ja) | 2023-09-08 |
| EP4192454A4 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116265462B (zh) | 一种具有抗肿瘤活性的杂环化合物及其用途 | |
| CN116171153A (zh) | 用于调节剪接的组合物 | |
| JP5820921B2 (ja) | 1,2−二置換複素環式化合物 | |
| US10138249B2 (en) | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | |
| TWI766882B (zh) | 新穎化合物類 | |
| US10259816B2 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
| US20200148703A1 (en) | Bromodomain inhibitors | |
| WO2022060951A1 (en) | Compositions for modulating splicing | |
| CN116568302A (zh) | 杂环取代的稠合γ-咔啉类衍生物、其制备方法、中间体及应用 | |
| WO2017223260A1 (en) | Pu.1 inhibitors | |
| WO2022060943A1 (en) | Compositions for modulating splicing | |
| WO2022116968A1 (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 | |
| CN116621846B (zh) | 双环杂环及三环杂环类化合物及其制备方法和医药用途 | |
| CN119874686A (zh) | 氘代苯并咪唑衍生物及其制备方法和用途 | |
| WO2022060944A1 (en) | Compositions for modulating splicing | |
| CN116478147A (zh) | 抑制rna解旋酶dhx33活性的氘代化合物、合成方法、药物组合物及用途 | |
| EP4514806B1 (en) | Compositions useful for modulating splicing | |
| CN118852164A (zh) | Parp选择性抑制剂 | |
| WO2024169848A1 (zh) | miR-124诱导剂及其制备方法和用途 | |
| CN118027024A (zh) | 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途 | |
| CN119403802A (zh) | 二并环类mat2a抑制剂及其用途 | |
| CN117024441A (zh) | 一种mat2a抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |